This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Piper Sandler Initiates SI-Bone With Overweight Rating, Price Target is $25 MT
Transcript : SI-BONE, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 08:30 AM
Morgan Stanley Raises SI-Bone Price Target to $26 From $25, Maintains Overweight Rating MT
Truist Securities Adjusts SI-Bone Price Target to $24 From $26, Maintains Buy Rating MT
Transcript : SI-BONE, Inc., Q4 2023 Earnings Call, Feb 26, 2024
Earnings Flash (SIBN) SI-BONE Posts Q4 Revenue $38.9M, vs. Street Est of $38.6M MT
SI-BONE, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
SI-BONE, Inc. Provides Earnings Guidance for the Year 2024 CI
Si-bone Insider Sold Shares Worth $808,591, According to a Recent SEC Filing MT
SI-Bone Implant Receives Expanded FDA Approval MT
SI-Bone Shares Up After Receiving FDA Approval for Expanded Device Use DJ
SI-BONE, Inc. Receives FDA 510(k) Clearance for a Smaller Diameter iFuse Bedrock Granite Implant with an Expanded Indication and Application CI
SI-Bone, Inc. Provides Revenue Guidance for the Fourth Quarter and Full Year 2023 CI
Truist Securities Adjusts Price Target on SI-Bone to $26 From $25, Maintains Buy Rating MT
Truist Securities Raises SI-Bone Price Target to $25 From $22, Maintains Buy Rating MT
Cantor Fitzgerald Adjusts SI-Bone's Price Target to $25 From $30, Maintains Overweight Rating MT
Morgan Stanley Adjusts Price Target on SI-Bone to $25 From $30, Maintains Overweight Rating MT
Needham Adjusts Price Target on SI-Bone to $25 From $32, Maintains Buy Rating MT
Transcript : SI-BONE, Inc., Q3 2023 Earnings Call, Nov 06, 2023
Earnings Flash (SIBN) SI-BONE Posts Q3 Revenue $34M MT
SI-BONE, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
SI-BONE, Inc. Increases Earnings Guidance for the Full Year 2023 CI
BofA Trims Price Target on SI-Bone to $24 From $33, Keeps Buy Rating MT
Si-bone Insider Sold Shares Worth $423,738, According to a Recent SEC Filing MT
Transcript : SI-BONE, Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-12-2023 09:30 AM
Chart SI-BONE, Inc.
More charts
SI-BONE, Inc. is a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy. The Company specializes in minimally invasive surgical implant systems to address sacroiliac joint dysfunction as well as address unmet clinical needs in pelvic fixation and management of pelvic fractures. The Company's products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. Its products include iFuse, iFuse-3D, iFuse-TORQ and iFuse Bedrock Granite. Within the United States, iFuse, iFuse-3D and iFuse-TORQ have clearances for applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma. Its first-generation iFuse, a machined triangular titanium implant, has a triangular cross section that resists twisting or rotation of the implant. The Company's second generation iFuse product, the iFuse-3D implant, is a patented titanium implant.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
15.42 USD
Average target price
26.22 USD
Spread / Average Target
+70.05%
Consensus
  1. Stock Market
  2. Equities
  3. SIBN Stock
  4. News SI-BONE, Inc.
  5. Si Bone : says Centene Establishes Positive Coverage Policy for its iFuse Implant System